Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts. This story matters for Finance & Markets readers tracking finance. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundingWire.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily finance & markets signal